The Lancet Oncology Publishes Phase I Data Demonstrating the Safety, Tolerability, and Preliminary Efficacy of Cornerstone Pharmaceuticals’ CPI-613 in Combination with Modified FOLFIRINOX in Patients

Press/Media: Press / Media

PeriodMay 9 2017

Media coverage

7

Media coverage

  • TitleThe Lancet Oncology Publishes Phase I Data Demonstrating the Safety, Tolerability, and Preliminary Efficacy of Cornerstone Pharmaceuticals’ CPI-613 in Combination with Modified FOLFIRINOX in Patients
    Media name/outletBioSpace
    CountryUnited States
    Date5/9/17
    PersonsAngela Alistar
  • TitleThe Lancet Oncology Publishes Phase I Data Demonstrating the Safety, Tolerability, and Preliminary Efficacy of Cornerstone Pharmaceuticals’ CPI-613 in Combination with Modified FOLFIRINOX in Patients with Metastatic Pancreatic Cancer
    Media name/outlet4 Traders
    CountryUnited States
    Date5/9/17
    PersonsAngela Alistar
  • TitleThe Lancet Oncology Publishes Phase I Data Demonstrating the Safety, Tolerability, and Preliminary Efficacy of Cornerstone Pharmaceuticals’ CPI-613 in Combination with Modified FOLFIRINOX in Patients with Metastatic Pancreatic Cancer
    Media name/outletPharmiWeb
    CountryUnited Kingdom
    Date5/9/17
    PersonsAngela Alistar
  • TitleThe Lancet Oncology Publishes Phase I Data Demonstrating the Safety, Tolerability, and Preliminary Efficacy of Cornerstone Pharmaceuticals’ CPI-613 in Combination with Modified FOLFIRINOX in Patients with Metastatic Pancreatic Cancer
    Media name/outletGlobeNewswire
    CountryUnited States
    Date5/9/17
    PersonsAngela Alistar
  • TitleThe Lancet Oncology Publishes Phase I Data Demonstrating the Safety, Tolerability, and Preliminary Efficacy of Cornerstone Pharmaceuticals’ CPI-613 in Combination with Modified FOLFIRINOX in Patients
    Media name/outletDaily Times Leader
    CountryUnited States
    Date5/9/17
    PersonsAngela Alistar
  • TitleThe Lancet Oncology Publishes Phase I Data Demonstrating the Safety, Tolerability, and Preliminary Efficacy of Cornerstone Pharmaceuticals’ CPI-613 in Combination with Modified FOLFIRINOX in Patients with Metastatic Pancreatic Cancer
    Media name/outletPR Distribution
    CountryPoland
    Date5/9/17
    PersonsAngela Alistar
  • TitleThe Lancet Oncology Publishes Phase I Data Demonstrating the Safety, Tolerability, and Preliminary Efficacy of Cornerstone Pharmaceuticals’ CPI-613 in Combination with Modified FOLFIRINOX in Patients with Metastatic Pancreati
    Media name/outletBizWire Express
    CountryIndia
    Date5/9/17
    PersonsAngela Alistar